From CIBC
Highlights From Neurogen's Insomnia Focused Panel Discussion
On 9/25, NRGN hosted a panel discussion on insomnia, featuring 3 key opinion leaders. The panel focused on 3 areas: current trends in the mgmt of insomnia, results of ph.II adipiplon (formerly NG2-73) studies, and the role of anxiety and other CNS disorders in chronic insomnia.
Tom Roth (Henry Ford Hospital) discussed the pharmacological mgmt of insomnia. Dr. Roth indicated that, despite the multitude of new drugs in development, GABA-targeting agents will remain the cornerstone of therapy due to their dramatic effects on sleep induction and maintenance.
Alan Lankford (Sleep Disorders Ctr of GA) discussed recently completed ph.IIb induction and maintenance trials of adipiplon. Dr. Lankford indicated that adipiplon's prelim LPS/WASO data were at least on par with current drugs. High sleep quality and lack of rebound were key adipiplon benefits.
Andrew Krystal (Duke Univ) discussed the importance of anxiolysis in sleep induction/maintenance. We believe adipiplon's anxiolytic properties, arising from its a-3 subtype preference, combined with its induction, maintenance, and sleep quality profile, may ultimately lead to a best-in-class agent. |
